Tamoxifen Monotherapy. NCCP National SACT Regimen. HSE.

Regulatory approval published by the Health Service Executive.

Citation

Tamoxifen Monotherapy, 2025, version number 5, NCCP National SACT Regimen, NCCP, viewed 26/03/2026, https://healthservice.hse.ie/documents/6357/253_v5_Tamoxifen_Monotherapy.pdf

Regulatory approvals

Approved indications from this document for cancer drugs containing at least one biomarker.

Indication	Statements
Adjuvant treatment of oestrogen receptor positive breast cancer in pre- or post-menopausal women.	1
Treatment of oestrogen receptor positive advanced breast cancer in pre- or post-menopausal women.	1

Therapeutic response

Precision oncology relationships for therapeutic response derived from this document.

Organization(s)	Biomarker(s)	Cancer type	Therapy(ies)
HSE (2)	ER positive	Invasive Breast Carcinoma	Tamoxifen